Layolis Fe 28 Shortage: What Providers and Prescribers Need to Know in 2026

Clinicians across primary care, obstetrics, and gynecology are increasingly fielding calls from patients who cannot locate their Layolis Fe 28 prescription. While Layolis Fe 28 is not currently listed in the FDA Drug Shortage Database, pharmacy-level availability gaps are a documented issue with niche chewable contraceptive formulations. This guide provides prescribers with the clinical context, substitution options, and patient support strategies needed to manage these situations effectively.

Clinical Overview of Layolis Fe 28

Layolis Fe 28 is a monophasic combination oral contraceptive containing 0.8 mg norethindrone and 0.025 mg (25 mcg) ethinyl estradiol per active tablet, packaged in a 24/4 format (24 active chewable hormone tablets + 4 chewable ferrous fumarate 75 mg placebo tablets). It is a generic of Generess Fe, manufactured by Actavis Pharma.

Clinical efficacy data: Pearl Index of 2.01 (95% CI: 1.21–3.14) pregnancies per 100 women-years in a study of 1,251 women aged 18–35 over 12,297 treatment cycles. The chewable formulation is beneficial for patients who have difficulty swallowing tablets or capsules, and the iron component helps support hemoglobin levels during menstruation.

Why Patients Are Having Trouble Filling This Prescription

Layolis Fe 28 is not in an FDA-declared shortage, but patients consistently report availability problems. Contributing factors include:

• Low-volume niche formulation: chewable oral contraceptives hold a small market share, leading to shallow pharmacy inventory depths.
• Generic fragmentation: at least four products share this market — Layolis Fe, Kaitlib Fe, Wymzya Fe, Zenchent Fe, and the brand Generess Fe — so individual products may see inconsistent wholesale orders.
• Formulary preferences: some pharmacy chains favor certain generics over others based on wholesaler contracts, further fragmenting availability.

Therapeutic Substitution Options

When Layolis Fe 28 is unavailable, the following options should be considered in clinical order of preference:

1. FDA-Rated Therapeutic Equivalents (AB Rating)

The following products are FDA-rated therapeutic equivalents to Generess Fe (the reference listed drug for Layolis Fe 28) and contain identical active ingredients:

• Kaitlib Fe (norethindrone 0.8 mg / EE 0.025 mg / ferrous fumarate 75 mg chewable) — 24/4 format, same bioequivalence profile.
• Wymzya Fe (norethindrone 0.8 mg / EE 0.025 mg / ferrous fumarate 75 mg chewable) — 24/4 format, same bioequivalence profile.
• Zenchent Fe — same formulation, may be available through different distribution channels.

2. Clinically Similar Alternatives (Require New Rx)

If therapeutically equivalent generics are also unavailable, consider the following based on patient history and clinical goals:

• Lo Loestrin Fe: Norethindrone acetate 1 mg / EE 10 mcg — very low-dose estrogen; appropriate for estrogen-sensitive patients. Brand-only, no generic.
• Yaz / Yasmin (generic: drospirenone/EE): Drospirenone 3 mg / EE 20 mcg — anti-androgenic progestin; consider for patients with acne or PMDD co-indication. Monitor potassium due to mild anti-mineralocorticoid effect.
• Sprintec / generic norgestimate-EE: Widely available, low cost, suitable for general contraception. Traditional 21/7 or 28-day format.
• Progestin-only pill (norethindrone 0.35 mg): Appropriate if estrogen is contraindicated (e.g., breastfeeding, history of migraine with aura, thromboembolic risk). Available as generic.

Prescribing Strategies to Reduce Access Problems

Consider these proactive prescribing practices to reduce the likelihood of patients experiencing supply gaps:

1. Write 90-day supply prescriptions when clinically appropriate to reduce monthly pharmacy touchpoints.
2. Include a DAW-0 (Dispense As Written 0 — generic substitution permitted) notation and pre-authorize substitution with therapeutically equivalent generics.
3. Direct patients to mail-order pharmacy options via their insurance benefit for reliable monthly supply.
4. Recommend medfinder.com/providers as a resource for patients struggling to locate their prescription — it calls local pharmacies on their behalf and texts the results.

Counseling Points for Patients Experiencing Supply Gaps

When counseling patients about supply gaps, emphasize:

• Missed doses reduce contraceptive efficacy — they should use backup contraception (condoms) until they've taken 7 consecutive active tablets.
• If a switch to a new formulation is made, treat it as starting a new pack and advise backup contraception for the first 7 days.
• Emergency contraception should be discussed if unprotected intercourse occurred during a supply gap exceeding 2+ missed active tablets.

The Bottom Line for Providers

Layolis Fe 28 is not in a formal shortage, but patients genuinely struggle to fill it. Pre-authorizing therapeutic substitution to Kaitlib Fe or Wymzya Fe and directing patients to pharmacy-finding services like medfinder are the most practical interventions. For more provider-specific guidance, see our provider guide to helping patients find Layolis Fe 28 in stock.